Literature DB >> 930942

Effect of plasma exchange on circulating immune complexes and antibody formation in patients treated with cyclophosphamide and prednisone.

R D Rossen, E M Hersh, J T Sharp, K B McCredie, F Gyorkey, W N Suki, G Eknoyan, M A Reisberg.   

Abstract

A patient with systemic lupus erythematosus (SLE) and a patient with an immune complex disease resembling Goodpasture's syndrome were treated with cyclophosphamide, prednisone and repeated plasma exchanges. Circulating immune complexes decreased, and symptoms of central nervous system disease remitted for up to 15 to 20 days after plasma exchange in the patient with SLE. In vitro lymphocyte blastogenic responses to antigens were also transiently increased on two occasions following treatment. In the second patient, decreases in circulating immune complexes and clinical improvement were ascribed chiefly to immunosuppressive drug treatment. Serum antibody to keyhole limpet hemocyanin was relatively unaffected by plasma exchange in both patients. These results suggest that plasma exchange may help to deplete circulating immune complexes or alter the equilibrium between soluble antigen and antibody which causes complexes to form and circulate. It may be less effective in reducing circulating antibody levels in patients who continue to produce new antibody.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 930942     DOI: 10.1016/0002-9343(77)90151-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

1.  Monthly plasmapheresis for systemic lupus erythematosus with diffuse proliferative glomerulonephritis: a pilot study.

Authors:  W F Clark; R M Lindsay; D C Cattran; W B Chodirker; C C Barnes; A L Linton
Journal:  Can Med Assoc J       Date:  1981-07-15       Impact factor: 8.262

2.  Apheresis enhances the selective removal of antinuclear antibodies in systemic lupus erythematosus.

Authors:  K K Colburn; G A Gusewitch; B S Statian Pooprasert; R H Weisbart
Journal:  Clin Rheumatol       Date:  1990-12       Impact factor: 2.980

3.  Plasmapheresis combined with lymphocytapheresis and cytotoxic drugs as a therapeutic modality in neuroimmunological diseases.

Authors:  M Valbonesi; F Montani; G Florio; D Zerbi; A Beltramelli
Journal:  Ital J Neurol Sci       Date:  1984-03

4.  Cerebral lupus erythematosus responding to plasmaphaeresis.

Authors:  D T Evans; M Giles; D J Horne; A J d'Apice; A Riglar; B H Toh
Journal:  Postgrad Med J       Date:  1981-04       Impact factor: 2.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.